Simoa BD-Tau Advantage PLUS Assay
Category: Analytical/Test
Developers: Quanterix Corporation
Product Description:The Simoa BD-Tau Advantage PLUS Assay advances neurodegenerative research with its ultrasensitive and selective measurement of brain-derived tau (BD-Tau) levels in serum, plasma and cerebrospinal fluid (CSF) samples. This assay could be a tool for furthering translational and clinical research in Alzheimer’s Disease (AD) and other neurodegenerative conditions. The Simoa BD-Tau Advantage PLUS is a digital immunoassay intended for the measurement of brain derived (BD) Tau in human plasma, serum, and CSF samples, facilitating research in neurodegenerative diseases. BD-Tau enhances our understanding of neurodegenerative diseases and is emerging as a blood-based biomarker that outperforms total Tau and Neurofilament light (NfL) in distinguishing AD from other neurodegenerative diseases. BD-Tau has been shown to be a more specific measurement of neurodegenerative disease than total Tau in blood in that it allows for the discrimination of CNS-originated Tau from those originating from peripheral tissues. The Simoa BD-Tau Advantage PLUS assay provides sensitive and selective measurement of BD-Tau proteins in biological samples. This assay offers new insights to advance research into AD and other neurological conditions and ensures reliable results for both large-scale and longitudinal studies.
Developers: Quanterix Corporation
Product Description:The Simoa BD-Tau Advantage PLUS Assay advances neurodegenerative research with its ultrasensitive and selective measurement of brain-derived tau (BD-Tau) levels in serum, plasma and cerebrospinal fluid (CSF) samples. This assay could be a tool for furthering translational and clinical research in Alzheimer’s Disease (AD) and other neurodegenerative conditions. The Simoa BD-Tau Advantage PLUS is a digital immunoassay intended for the measurement of brain derived (BD) Tau in human plasma, serum, and CSF samples, facilitating research in neurodegenerative diseases. BD-Tau enhances our understanding of neurodegenerative diseases and is emerging as a blood-based biomarker that outperforms total Tau and Neurofilament light (NfL) in distinguishing AD from other neurodegenerative diseases. BD-Tau has been shown to be a more specific measurement of neurodegenerative disease than total Tau in blood in that it allows for the discrimination of CNS-originated Tau from those originating from peripheral tissues. The Simoa BD-Tau Advantage PLUS assay provides sensitive and selective measurement of BD-Tau proteins in biological samples. This assay offers new insights to advance research into AD and other neurological conditions and ensures reliable results for both large-scale and longitudinal studies.
